Cure8 research brief
Cure8 research brief
The study suggests pulmonary nodules are more common in people with Crohn’s disease and that age and certain medications (not disease phenotype) may better predict nodule burden — information that could influence how clinicians monitor lung findings in IBD patients.
Adults with Crohn's disease; clinicians following IBD patients (gastroenterologists, pulmonologists, radiologists); researchers of extraintestinal manifestations and medication effects.
The study used inverse probability weighting on a large real-world cohort to compare nodule counts and their change over time. Crohn’s disease was associated with higher counts of several nodule subtypes (for example, solid nodules).
Over time, patients with Crohn’s saw greater reductions in some nodules (<6 mm and solid nodules) but slightly faster growth of persistent small nodules. Age emerged as the strongest predictor of nodule burden. Use of adalimumab was associated with fewer non-solid and 6–8 mm nodules in adjusted analyses.
Disease phenotype and extraintestinal manifestations did not predict nodule features.
This is an abstract-level summary of a retrospective multicenter cohort; observational associations cannot establish causality. Medication associations may be confounded by treatment selection. Full-text review is needed for details on imaging protocols, nodule adjudication, and adjustment variables.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.